| Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2415 | 2016 |
| ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up N Colombo, C Creutzberg, F Amant, T Bosse, A González-Martín, ... International Journal of Gynecologic Cancer 26 (1), 2016 | 1890 | 2016 |
| A pooled analysis of bone marrow micrometastasis in breast cancer S Braun, FD Vogl, B Naume, W Janni, MP Osborne, RC Coombes, ... New England journal of medicine 353 (8), 793-802, 2005 | 1658 | 2005 |
| ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma N Concin, X Matias-Guiu, I Vergote, D Cibula, MR Mirza, S Marnitz, ... International Journal of Gynecologic Cancer 31 (1), 2021 | 1367 | 2021 |
| Epigenetic stem cell signature in cancer M Widschwendter, H Fiegl, D Egle, E Mueller-Holzner, G Spizzo, C Marth, ... Nature genetics 39 (2), 157-158, 2007 | 1223 | 2007 |
| Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer AE Teschendorff, U Menon, A Gentry-Maharaj, SJ Ramus, ... Genome research 20 (4), 440-446, 2010 | 924 | 2010 |
| Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up C Marth, F Landoni, S Mahner, M McCormack, A Gonzalez-Martin, ... Annals of Oncology 28, iv72-iv83, 2017 | 786 | 2017 |
| The expression of the regulatory T cell–specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer D Wolf, AM Wolf, H Rumpold, H Fiegl, AG Zeimet, E Muller-Holzner, ... Clinical cancer research 11 (23), 8326-8331, 2005 | 651 | 2005 |
| Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease A Kraft, K Weindel, A Ochs, C Marth, J Zmija, P Schumacher, C Unger, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 1999 | 624 | 1999 |
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial M Gnant, G Pfeiler, PC Dubsky, M Hubalek, R Greil, R Jakesz, V Wette, ... The Lancet 386 (9992), 433-443, 2015 | 580 | 2015 |
| FBXW7/hCDC4 is a general tumor suppressor in human cancer S Akhoondi, D Sun, N von der Lehr, S Apostolidou, K Klotz, A Maljukova, ... Cancer research 67 (19), 9006-9012, 2007 | 575 | 2007 |
| A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms P Harter, J Sehouli, D Lorusso, A Reuss, I Vergote, C Marth, JW Kim, ... New England Journal of Medicine 380 (9), 822-832, 2019 | 496 | 2019 |
| Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy M Gnant, B Mlineritsch, G Luschin-Ebengreuth, F Kainberger, ... The lancet oncology 9 (9), 840-849, 2008 | 446 | 2008 |
| 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer GCE Stuart, H Kitchener, M Bacon, C Marth, T Thigpen, E Trimble Int J Gynecol Cancer 21 (4), 750-755, 2011 | 444 | 2011 |
| Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen M Widschwendter, KD Siegmund, HM Müller, H Fiegl, C Marth, ... Cancer research 64 (11), 3807-3813, 2004 | 427 | 2004 |
| DNA methylation in serum of breast cancer patients: an independent prognostic marker HM Muller, A Widschwendter, H Fiegl, L Ivarsson, G Goebel, E Perkmann, ... Cancer research 63 (22), 7641-7645, 2003 | 418 | 2003 |
| Incorporation of pazopanib in maintenance therapy of ovarian cancer A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo, M Friedlander, ... Journal of clinical oncology 32 (30), 3374-3382, 2014 | 380 | 2014 |
| Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer B Eibl, H Schwaighofer, D Nachbaur, C Marth, A Gachter, R Knapp, ... | 368 | 1996 |
| hCDC4 Gene Mutations in Endometrial Cancer CH Spruck, H Strohmaier, O Sangfelt, HM Muller, M Hubalek, ... Cancer research 62 (16), 4535-4539, 2002 | 355 | 2002 |
| Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial BJ Monk, A Poveda, I Vergote, F Raspagliesi, K Fujiwara, DS Bae, ... The lancet oncology 15 (8), 799-808, 2014 | 348 | 2014 |
